Related Experiment Video

Updated: Aug 18, 2026

Cardiac Response to β-Adrenergic Stimulation Determined by Pressure-Volume Loop Analysis
08:05

Cardiac Response to β-Adrenergic Stimulation Determined by Pressure-Volume Loop Analysis

Published on: May 19, 2021

Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in

Pascal de Groote1, Nicole Helbecque, Nicolas Lamblin

  • 1Service de Cardiologie C, Hôpital Cardiologique, Centre Hospitalier Universitaire de Lille, Lille, France. pdegroote@chru-lille.fr

Pharmacogenetics and Genomics
|April 30, 2005
PubMed

Insights

Beta-blockers benefit stable congestive heart failure (CHF) patients, improving ejection fraction. However, common beta-adrenergic receptor (betaAR) gene variations do not explain individual patient responses to these crucial heart failure medications.

Area of Science:

  • Cardiology
  • Pharmacogenomics

Background:

  • Beta-blockers are established treatments for stable congestive heart failure (CHF), improving left ventricular ejection fraction (LVEF) and reducing mortality.
  • Interindividual variability exists in patient response to beta-blocker therapy for CHF.

Purpose of the Study:

  • To investigate the association between genetic variations in beta1 and beta2 adrenergic receptor (AR) genes and the therapeutic effects of beta-blockade in stable CHF patients.

Main Methods:

  • 199 stable CHF patients, treatment-naïve to beta-blockers, were assessed using echocardiography and radionuclide angiography before and 3 months after maximal tolerated beta-blocker dose.
  • Genotyping was performed for five common polymorphisms in the beta1AR and beta2AR genes: beta1ARGly389Arg, beta1ARSer49Gly, beta2ARGly16Arg, beta2ARGln27Glu, and beta2ARThr164Ile.

Main Results:

  • Beta-blockade significantly reduced heart rate and increased LVEF (from 30±10% to 40±13%, P<0.0001).
  • No significant association was found between the five studied betaAR polymorphisms and heart rate or LVEF changes in response to beta-blockade.
  • The investigated betaAR gene polymorphisms did not account for the observed interindividual variability in treatment response.

Conclusions:

  • Common genetic variations in beta1AR and beta2AR genes do not explain the variability in response to beta-blockers in patients with stable CHF.
  • Further research is needed to identify genetic or other factors influencing individual responses to beta-blocker therapy in CHF.

Related Concept Videos

Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Antihypertensive Drugs: Types of &#946;-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Adrenergic Antagonists: Chemistry and Classification of &#946;-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
Antihypertensive Drugs: Action of &#946;1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Adrenergic Antagonists: &#593; and &#946;-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...